Healthequity (HQY) Stock Forecast & Price Target

Compare

823 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HQY Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Healthequity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HQY Stock 12 Month Forecast

Average Price Target

$121.85

▲(24.72%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Healthequity in the last 3 months. The average price target is $121.85 with a high forecast of $130.00 and a low forecast of $104.00. The average price target represents a 24.72% change from the last price of $97.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"76":"$76","131":"$131","89.75":"$89.8","103.5":"$103.5","117.25":"$117.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$121.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$104.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[76,89.75,103.5,117.25,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.89,104.97538461538461,107.06076923076922,109.14615384615385,111.23153846153846,113.31692307692308,115.40230769230769,117.4876923076923,119.57307692307693,121.65846153846154,123.74384615384615,125.82923076923078,127.91461538461539,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.89,104.34846153846154,105.80692307692307,107.26538461538462,108.72384615384615,110.18230769230769,111.64076923076922,113.09923076923077,114.5576923076923,116.01615384615384,117.47461538461538,118.93307692307692,120.39153846153846,{"y":121.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.89,102.97538461538461,103.06076923076922,103.14615384615385,103.23153846153846,103.31692307692308,103.40230769230769,103.48769230769231,103.57307692307693,103.65846153846154,103.74384615384615,103.82923076923078,103.91461538461539,{"y":104,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.62,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.87,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.56,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$130.00

Average Price Target$121.85

Lowest Price Target$104.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$107

Hold

9.52%

Upside

Downgraded

07/19/25

Healthequity's strong financial performance and positive corporate actions are the most significant factors boosting the overall score. However, high valuation metrics and neutral technical indicators weigh down the score. The earnings call provided positive insights, but economic uncertainties and fraud costs pose challenges.

Gregory PetersRaymond James

Raymond James

$101.83→$120

Buy

22.82%

Upside

Reiterated

07/08/25

Raymond James Sticks to Their Buy Rating for Healthequity (HQY)

Steven ValiquetteMizuho Securities

Mizuho Securities

$126

Buy

28.97%

Upside

Reiterated

07/02/25

Mizuho Securities Remains a Buy on Healthequity (HQY)

Stan BerenshteynWells Fargo

Wells Fargo

$125

Buy

27.94%

Upside

Assigned

06/29/25

Buy Rating for HealthEquity: Legislative Developments and Market Growth Potential

Allen LutzBank of America Securities

Bank of America Securities

$125

Buy

27.94%

Upside

Reiterated

06/17/25

Buy Rating for Healthequity Amid Legislative Opportunities and Market Expansion Potential

Glen SantangeloJefferies

Jefferies

$118→$130

Buy

33.06%

Upside

Reiterated

06/12/25

Healthequity (HQY) Gets a Buy from Jefferies

Alexander ParisBarrington

Barrington

$112→$125

Buy

27.94%

Upside

Reiterated

06/05/25

HealthEquity's Strong Financial Performance and Optimistic Guidance Justify Buy Rating and Increased Price Target

George HillDeutsche Bank

Deutsche Bank

$98→$115

Buy

17.71%

Upside

Reiterated

06/05/25

HealthEquity price target raised to $115 from $98 at Deutsche BankHealthEquity price target raised to $115 from $98 at Deutsche Bank

Anne SamuelJ.P. Morgan

J.P. Morgan

$100→$125

Buy

27.94%

Upside

Reiterated

06/05/25

J.P. Morgan Remains a Buy on Healthequity (HQY)

Scott SchoenhausKeyBanc

KeyBanc

$100→$125

Buy

27.94%

Upside

Reiterated

06/04/25

Healthequity (HQY) Receives a Buy from KeyBanc

Constantine DavidesCitizens JMP

Citizens JMP

$110→$117

Buy

19.75%

Upside

Reiterated

06/04/25

HealthEquity price target raised to $117 from $110 at Citizens JMPHealthEquity price target raised to $117 from $110 at Citizens JMP

David LarsenBTIG

BTIG

$130

Buy

33.06%

Upside

Reiterated

06/04/25

Healthequity's Strong Financial Performance and Strategic Initiatives Drive Buy Rating

David RomanGoldman Sachs

Goldman Sachs

$94→$104

Hold

6.45%

Upside

Reiterated

06/03/25

Healthequity (HQY) Receives a Hold from Goldman Sachs

Daniel PerlinRBC Capital

RBC Capital

$112→$117

Buy

19.75%

Upside

Reiterated

06/03/25

RBC Capital Remains a Buy on Healthequity (HQY)

Stephanie DavisBarclays

Barclays

$104

Buy

6.45%

Upside

Assigned

11/13/24

Healthequity (HQY) Receives a Buy from Barclays

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$107

Hold

9.52%

Upside

Downgraded

07/19/25

Gregory PetersRaymond James

Raymond James

$101.83→$120

Buy

22.82%

Upside

Reiterated

07/08/25

Raymond James Sticks to Their Buy Rating for Healthequity (HQY)

Steven ValiquetteMizuho Securities

Mizuho Securities

$126

Buy

28.97%

Upside

Reiterated

07/02/25

Mizuho Securities Remains a Buy on Healthequity (HQY)

Stan BerenshteynWells Fargo

Wells Fargo

$125

Buy

27.94%

Upside

Assigned

06/29/25

Buy Rating for HealthEquity: Legislative Developments and Market Growth Potential

Allen LutzBank of America Securities

Bank of America Securities

$125

Buy

27.94%

Upside

Reiterated

06/17/25

Buy Rating for Healthequity Amid Legislative Opportunities and Market Expansion Potential

Glen SantangeloJefferies

Jefferies

$118→$130

Buy

33.06%

Upside

Reiterated

06/12/25

Healthequity (HQY) Gets a Buy from Jefferies

Alexander ParisBarrington

Barrington

$112→$125

Buy

27.94%

Upside

Reiterated

06/05/25

HealthEquity's Strong Financial Performance and Optimistic Guidance Justify Buy Rating and Increased Price Target

George HillDeutsche Bank

Deutsche Bank

$98→$115

Buy

17.71%

Upside

Reiterated

06/05/25

HealthEquity price target raised to $115 from $98 at Deutsche BankHealthEquity price target raised to $115 from $98 at Deutsche Bank

Anne SamuelJ.P. Morgan

J.P. Morgan

$100→$125

Buy

27.94%

Upside

Reiterated

06/05/25

J.P. Morgan Remains a Buy on Healthequity (HQY)

Scott SchoenhausKeyBanc

KeyBanc

$100→$125

Buy

27.94%

Upside

Reiterated

06/04/25

Healthequity (HQY) Receives a Buy from KeyBanc

Constantine DavidesCitizens JMP

Citizens JMP

$110→$117

Buy

19.75%

Upside

Reiterated

06/04/25

HealthEquity price target raised to $117 from $110 at Citizens JMPHealthEquity price target raised to $117 from $110 at Citizens JMP

David LarsenBTIG

BTIG

$130

Buy

33.06%

Upside

Reiterated

06/04/25

Healthequity's Strong Financial Performance and Strategic Initiatives Drive Buy Rating

David RomanGoldman Sachs

Goldman Sachs

$94→$104

Hold

6.45%

Upside

Reiterated

06/03/25

Healthequity (HQY) Receives a Hold from Goldman Sachs

Daniel PerlinRBC Capital

RBC Capital

$112→$117

Buy

19.75%

Upside

Reiterated

06/03/25

RBC Capital Remains a Buy on Healthequity (HQY)

Stephanie DavisBarclays

Barclays

$104

Buy

6.45%

Upside

Assigned

11/13/24

Healthequity (HQY) Receives a Buy from Barclays

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Healthequity

1 Month

xxx

Success Rate

13/21 ratings generated profit

Average Return

+0.31%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +0.31% per trade.

3 Months

xxx

Success Rate

18/29 ratings generated profit

Average Return

+7.70%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.07% of your transactions generating a profit, with an average return of +7.70% per trade.

1 Year

Stephanie DavisBarclays

Success Rate

28/34 ratings generated profit

Average Return

+15.39%

assigned a buy rating 8 months ago

Copying Stephanie Davis's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +15.39% per trade.

2 Years

xxx

Success Rate

22/25 ratings generated profit

Average Return

+26.64%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.00% of your transactions generating a profit, with an average return of +26.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HQY Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HQY has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HQY average Analyst price target in the past 3 months is 121.85.

Each month's total comprises the sum of three months' worth of ratings.

HQY Financial Forecast

HQY Earnings Forecast

Next quarter’s earnings estimate for HQY is $0.92 with a range of $0.86 to $0.97. The previous quarter’s EPS was $0.97. HQY beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.08% of the time in the same period. In the last calendar year HQY has Outperformed its overall industry.

HQY Sales Forecast

Next quarter’s sales forecast for HQY is $320.75M with a range of $313.56M to $327.24M. The previous quarter’s sales results were $330.84M. HQY beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year HQY has Outperformed its overall industry.

HQY Stock Forecast FAQ

What is HQY’s average 12-month price target, according to analysts?

Based on analyst ratings, Healthequity’s 12-month average price target is 121.85.

What is HQY’s upside potential, based on the analysts’ average price target?

Healthequity has 24.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HQY a Buy, Sell or Hold?

Healthequity has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Healthequity’s price target?

The average price target for Healthequity is 121.85. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $130.00 ,the lowest forecast is $104.00. The average price target represents 24.72% Increase from the current price of $97.7.

What do analysts say about Healthequity?

Healthequity’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of HQY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Healthequity (HQY) Stock Forecast & Price Target

HQY Analyst Ratings

HQY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Healthequity

HQY Analyst Recommendation Trends

HQY Financial Forecast

HQY Earnings Forecast

HQY Sales Forecast

HQY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts